Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to offer a promising step forward for body treatment. Initial human tests have demonstrated considerable losses in abdominal mass , conceivably outperforming ex